Compare Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Innov-100 0DTE Covered Call Strat ETF vs Sana Biotechnology Inc — how do they compare? Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.64, while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| QDTE | SANA | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $36.60 | $5.92 |
52-Week Low | $26.85 | $2.68 |
Market Cap | — | $879.40M |
Enterprise Value | — | $853.59M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTE trades at $29.22, up 0.31% on the day, with technical indicators signaling a bearish trend. The ETF employs a weekly covered call strategy on the Innovation-100 index, generating high distribution yields. Recent news highlights scrutiny over its fee structure and yield sustainability amid declining volatility. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook is cautious due to bearish technicals and yield compression risks. Opportunities exist for income-focused investors seeking weekly distributions, but risks include fee drag and volatility dependence. Investor sentiment is mixed, with media questioning yield math while acknowledging competitive returns in certain periods.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
